
Cinclus Pharma (Q3 review) - Pivotal studies underway

Redeye provides a research update following the Q3 report published by Cinclus earlier today. The financials in the report did not contain any major surprises. Instead, the headline for the quarter is the initiation of the company's pivotal phase III study. With recruitment in full swing, we await topline results anticipated in H2 2026e.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

Cinclus Pharma (Q3 review) - Pivotal studies underway